These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 32119749

  • 1. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
    Recker R, Dempster D, Langdahl B, Giezek H, Clark S, Ellis G, de Villiers T, Valter I, Zerbini CA, Cohn D, Santora A, Duong LT.
    J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT, Clark S, Pickarski M, Giezek H, Cohn D, Massaad R, Stoch SA.
    Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
    [Abstract] [Full Text] [Related]

  • 6. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D.
    Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
    [Abstract] [Full Text] [Related]

  • 7. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 8. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW.
    Clin Interv Aging; 2012 Dec; 7():235-47. PubMed ID: 22866001
    [Abstract] [Full Text] [Related]

  • 9. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
    Binkley N, Orwoll E, Chapurlat R, Langdahl BL, Scott BB, Giezek H, Santora AC.
    Osteoporos Int; 2021 Jan; 32(1):173-184. PubMed ID: 33200257
    [Abstract] [Full Text] [Related]

  • 11. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
    Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, de Papp A.
    J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
    [Abstract] [Full Text] [Related]

  • 12. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

  • 13. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, Dardzinski B, Cabal A, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [Abstract] [Full Text] [Related]

  • 14. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA.
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [Abstract] [Full Text] [Related]

  • 15. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A.
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [Abstract] [Full Text] [Related]

  • 16. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
    Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, Duong LT.
    J Bone Miner Res; 2012 Mar; 27(3):524-37. PubMed ID: 22113921
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
    Chen R, Chen C, Geng B, Yang C, Xiao H, Yang F, Wang H, Xia Y.
    Arch Osteoporos; 2023 May 11; 18(1):67. PubMed ID: 37169994
    [Abstract] [Full Text] [Related]

  • 18. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
    Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A.
    J Bone Miner Res; 2012 Nov 11; 27(11):2251-8. PubMed ID: 22777865
    [Abstract] [Full Text] [Related]

  • 19. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
    Duong LT, Crawford R, Scott K, Winkelmann CT, Wu G, Szczerba P, Gentile MA.
    Bone; 2016 Dec 11; 93():86-96. PubMed ID: 27639811
    [Abstract] [Full Text] [Related]

  • 20. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
    Schultz TC, Valenzano JP, Verzella JL, Umland EM.
    Womens Health (Lond); 2015 Nov 11; 11(6):805-14. PubMed ID: 26344800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.